D-domain (round binding site)
Use this icon in our BioRender software along with 1000s of others. Create your next scientific figure in minutes!
SIGN UP FREE[{"image":"https://icons.biorender.com/w75xh75/63dd2a0452f9f70020b4cd7f/d-domain-round-binding-site.png","waterMarkImage":"https://icons.biorender.com/w550xh620/63dd2a0452f9f70020b4cd7f/d-domain-round-binding-site.png"},{"image":"https://icons.biorender.com/w75xh75/63dd2a0452f9f70020b4cd7e/d-domain-round-binding-site.png","waterMarkImage":"https://icons.biorender.com/w550xh620/63dd2a0452f9f70020b4cd7e/d-domain-round-binding-site.png"},{"image":"https://icons.biorender.com/w75xh75/63dd2a0452f9f70020b4cd7d/d-domain-round-binding-site.png","waterMarkImage":"https://icons.biorender.com/w550xh620/63dd2a0452f9f70020b4cd7d/d-domain-round-binding-site.png"},{"image":"https://icons.biorender.com/w75xh75/63dd2a0452f9f70020b4cd7c/d-domain-round-binding-site.png","waterMarkImage":"https://icons.biorender.com/w550xh620/63dd2a0452f9f70020b4cd7c/d-domain-round-binding-site.png"},{"image":"https://icons.biorender.com/w75xh75/63dd2a0452f9f70020b4cd7b/d-domain-round-binding-site.png","waterMarkImage":"https://icons.biorender.com/w550xh620/63dd2a0452f9f70020b4cd7b/d-domain-round-binding-site.png"},{"image":"https://icons.biorender.com/w75xh75/63dd2a0452f9f70020b4cd7a/d-domain-round-binding-site.png","waterMarkImage":"https://icons.biorender.com/w550xh620/63dd2a0452f9f70020b4cd7a/d-domain-round-binding-site.png"},{"image":"https://icons.biorender.com/w75xh75/63dd2a0452f9f70020b4cd79/d-domain-round-binding-site.png","waterMarkImage":"https://icons.biorender.com/w550xh620/63dd2a0452f9f70020b4cd79/d-domain-round-binding-site.png"},{"image":"https://icons.biorender.com/w75xh75/63dd2a0452f9f70020b4cd78/d-domain-round-binding-site.png","waterMarkImage":"https://icons.biorender.com/w550xh620/63dd2a0452f9f70020b4cd78/d-domain-round-binding-site.png"},{"image":"https://icons.biorender.com/w75xh75/63dd2a0452f9f70020b4cd77/d-domain-round-binding-site.png","waterMarkImage":"https://icons.biorender.com/w550xh620/63dd2a0452f9f70020b4cd77/d-domain-round-binding-site.png"},{"image":"https://icons.biorender.com/w75xh75/63dd2a0452f9f70020b4cd76/d-domain-round-binding-site.png","waterMarkImage":"https://icons.biorender.com/w550xh620/63dd2a0452f9f70020b4cd76/d-domain-round-binding-site.png"},{"image":"https://icons.biorender.com/w75xh75/63dd2a0452f9f70020b4cd75/d-domain-round-binding-site.png","waterMarkImage":"https://icons.biorender.com/w550xh620/63dd2a0452f9f70020b4cd75/d-domain-round-binding-site.png"},{"image":"https://icons.biorender.com/w75xh75/63dd2a0452f9f70020b4cd74/d-domain-round-binding-site.png","waterMarkImage":"https://icons.biorender.com/w550xh620/63dd2a0452f9f70020b4cd74/d-domain-round-binding-site.png"},{"image":"https://icons.biorender.com/w75xh75/63dd2a0452f9f70020b4cd73/d-domain-round-binding-site.png","waterMarkImage":"https://icons.biorender.com/w550xh620/63dd2a0452f9f70020b4cd73/d-domain-round-binding-site.png"},{"image":"https://icons.biorender.com/w75xh75/63dd2a0452f9f70020b4cd72/d-domain-round-binding-site.png","waterMarkImage":"https://icons.biorender.com/w550xh620/63dd2a0452f9f70020b4cd72/d-domain-round-binding-site.png"},{"image":"https://icons.biorender.com/w75xh75/63dd2a0452f9f70020b4cd71/d-domain-round-binding-site.png","waterMarkImage":"https://icons.biorender.com/w550xh620/63dd2a0452f9f70020b4cd71/d-domain-round-binding-site.png"},{"image":"https://icons.biorender.com/w75xh75/63dd2a0452f9f70020b4cd70/d-domain-round-binding-site.png","waterMarkImage":"https://icons.biorender.com/w550xh620/63dd2a0452f9f70020b4cd70/d-domain-round-binding-site.png"},{"image":"https://icons.biorender.com/w75xh75/63dd2a0452f9f70020b4cd6f/d-domain-round-binding-site.png","waterMarkImage":"https://icons.biorender.com/w550xh620/63dd2a0452f9f70020b4cd6f/d-domain-round-binding-site.png"},{"image":"https://icons.biorender.com/w75xh75/63dd2a0452f9f70020b4cd6e/d-domain-round-binding-site.png","waterMarkImage":"https://icons.biorender.com/w550xh620/63dd2a0452f9f70020b4cd6e/d-domain-round-binding-site.png"},{"image":"https://icons.biorender.com/w75xh75/63dd2a0452f9f70020b4cd6d/d-domain-round-binding-site.png","waterMarkImage":"https://icons.biorender.com/w550xh620/63dd2a0452f9f70020b4cd6d/d-domain-round-binding-site.png"},{"image":"https://icons.biorender.com/w75xh75/63dd2a0452f9f70020b4cd6c/d-domain-round-binding-site.png","waterMarkImage":"https://icons.biorender.com/w550xh620/63dd2a0452f9f70020b4cd6c/d-domain-round-binding-site.png"},{"image":"https://icons.biorender.com/w75xh75/63dd2a0452f9f70020b4cd6b/d-domain-round-binding-site.png","waterMarkImage":"https://icons.biorender.com/w550xh620/63dd2a0452f9f70020b4cd6b/d-domain-round-binding-site.png"},{"image":"https://icons.biorender.com/w75xh75/63dd2a0452f9f70020b4cd6a/d-domain-round-binding-site.png","waterMarkImage":"https://icons.biorender.com/w550xh620/63dd2a0452f9f70020b4cd6a/d-domain-round-binding-site.png"},{"image":"https://icons.biorender.com/w75xh75/63dd2a0452f9f70020b4cd69/d-domain-round-binding-site.png","waterMarkImage":"https://icons.biorender.com/w550xh620/63dd2a0452f9f70020b4cd69/d-domain-round-binding-site.png"},{"image":"https://icons.biorender.com/w75xh75/63dd2a0452f9f70020b4cd68/d-domain-round-binding-site.png","waterMarkImage":"https://icons.biorender.com/w550xh620/63dd2a0452f9f70020b4cd68/d-domain-round-binding-site.png"},{"image":"https://icons.biorender.com/w75xh75/63dd2a0452f9f70020b4cd67/d-domain-round-binding-site.png","waterMarkImage":"https://icons.biorender.com/w550xh620/63dd2a0452f9f70020b4cd67/d-domain-round-binding-site.png"},{"image":"https://icons.biorender.com/w75xh75/63dd2a0452f9f70020b4cd66/d-domain-round-binding-site.png","waterMarkImage":"https://icons.biorender.com/w550xh620/63dd2a0452f9f70020b4cd66/d-domain-round-binding-site.png"}]
Keywords
D-domain,d domain,binding site,generic protein,Arcellx,ddCAR,ARC-SparX,sparx,protein,domain,binding domain,antigen binding,antigen receptor,recognition,CAR-T cell therapy,chimeric antigen receptor,synthetic,binding agent,synthetic binding agent,biotechnology,target-binding domain,cell therapy,immunotherapy,immune therapy,cancer treatment,cancer research,oncology,target specificity,binding affinity,active site,space-filled protein,space-filling,molecule,generic molecule,macromolecule,round,circular,circle,semi-circle,semicircle